Nanopath receives Federal Grants for Women's Health Diagnostics

A point-of-care diagnostics company, Nanopath has received a federal grant of $4 million from National Institutes of Health (NIH) and National Science Foundation (NSF).

The funding has been provided in order to assist Nanopath’s diagnostic platform’s development that has a focus on pelvic and gynecologic infections and diseases. During the competitive Small Business Innovation Research (SBIR) Program, the grants have been provided to the firm.

Ph.D. holder, co-founder and CEO of Nanopath, Amogha Tadimety stated, “This funding is a tremendous vote of confidence in Nanopath’s ability to transform molecular diagnostics and enable providers to move away from the traditional view of disease-specific diagnostic testing, and towards patient-centric testing. The outcomes of this grant-funded work could lay the groundwork for a new era of clinically informative diagnostics at any site-of-care, changing the paradigm of women’s healthcare.”

Dividing, NIH has given $3 million grant and NSF has provided $1 million grant for the advancement of Women’s Health Diagnostics. In conclusion, the firm has a total funding of over $15 million since it has raised a $10 million Series A in the year 2022.

Additionally, Ph.D., co-founder and CTO of Nanopath, Alison Burklund added, “The groundbreaking data, workflows and prototypes developed by our team over the last year formed the foundation of our applications for both grants. Nanopath is commercializing a novel technology that has never before been used for molecular diagnostics. Support from NSF, NIH, and the broader scientific community will catalyze our commercial development.”